€653.20
Your prediction
Regeneron Pharmaceuticals Inc. Stock
Regeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Pros and Cons of Regeneron Pharmaceuticals Inc. in the next few years
Pros
Cons
Performance of Regeneron Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 0.460% | -0.214% | -3.430% | 4.245% | -1.508% | -6.859% | 65.640% |
| Incyte Corp. | 0.730% | -2.032% | -4.885% | 29.766% | -3.823% | 18.786% | 22.653% |
| IQVIA Holdings Inc. | 0.420% | -4.089% | 2.633% | -13.752% | -25.298% | -21.892% | -8.703% |
| Exact Sciences | -0.110% | 0.269% | 2.829% | 125.580% | 3.340% | 51.226% | -16.695% |
Comments
News
Is Eli Lilly's Weight Loss Empire in Trouble?
Over the past two years, Eli Lilly (NYSE: LLY) has established itself as the leader in the weight loss market. That's thanks to the company's tirzepatide, a compound sold under the brand name
In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making
A multibagger stock is one that has doubled your money or more. Peter Lynch, the highly respected investment manager who ran the Magellan Fund for 14 years, coined the term in his book, One Up on
2 Underrated Weight Loss Stocks to Buy Now
Investors who want to capitalize on the growing weight loss market might be tempted to turn to the current leaders in the field, Eli Lilly and Novo Nordisk. Both companies are worth serious